Telix Pharmaceuticals Begins Phase 3 Trial for Prostate Cancer Diagnostics

Telix Pharmaceuticals Limited (NASDAQ:TLX) is among the best stocks with the highest upside potential. On September 10, 2025, Telix Pharmaceuticals Limited (NASDAQ:TLX) announced the dosing of the first patient in a Phase 3 clinical trial, designed to enhance the indications for Illuccix® and Gozellix® to incorporate prostate cancer diagnosis.

Biopsy of the Prostate Avoidance Stratification Study, or more commonly referred to as BiPASS, is the first registration-enabling study to assess whether the MRI and PSMA-PET imaging combination can actually enhance sensitivity and specificity in diagnosing prostate cancer. While enrolling 204 patients in Australia and the United States, Telix Pharmaceuticals Limited (NASDAQ:TLX) is committed to expanding on the research on the benefits of PSMA-PET and MRI.

As stated by Prof. Costello, Founder and Director, APC,

“Combining MRI and PSMA-PET imaging has the potential to improve both the patient experience and diagnostic accuracy. As such, being part of this study is very important to the APC and our patients.”

Telix Pharmaceuticals Limited (NASDAQ:TLX) is an Australian commercial-stage biopharmaceutical company that develops and commercializes therapeutic and diagnostic radiopharmaceuticals. Incepted in 2015, the company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions.

While we acknowledge the potential of TLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.